Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Focal onset seizures Clinical criteria: The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient, AND The condition must have failed to be controlled satisfactorily by at least one other antiseizure medication. Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“Tiagabine is a potent and selective inhibitor of both neuronal and glial GABA (γ-amino-butyric acid) uptake, resulting in an increase in GABAergic mediated inhibition in the brain.”
“The elimination half-life (t1/2) of tiagabine is 7 to 9 hours in normal volunteers.”
“Tiagabine is metabolised in the liver mainly by the cytochrome P450 isoenzyme CYP3A, with renal clearance being negligible.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.